GENERAL INFORMATION
Half-life modulating strategies - an introduction (Roland Kontermann)

Pharmacokinetics and half-life protein of therapeutics (Bernd Meibohm)

HALF-LIFE EXTENSION THROUGH CHEMICAL AND POSTTRANSLATIONAL MODIFICATIONS
Half-life extension through PEGylation (Simona Jevsevar and Menci Kunstelj)

Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics
(Uli Binder and Arne Skerra)

Half-life extension through O-glyosylation (Fuad Fares)

Polysialic acid and polysialylation to modulate antibody pharmacokinetics (Antony Constantinou, Chen Chen and Mahendra P. Deonarain)

Half-life extension through HESylation (Thomas Hey, Helmut Knoller and Peter Vorstheim)

HALF-LIFE MODULATION INVOLVING RECYCLING BY THE NEONATAL FC RECEPTOR
The biology of FcRn (Jonghan Kim)

Half-life extension by fusion to the Fc region (Jalal A. Jazayeri and Graeme J Carroll)

Monomeric Fc fusion Technology: an approach to create long lasting clotting factors (Jennifer A. Dumont, Xiaomei Jei, Robert T. Peters, Alvin Luk, Glenn F. Pierce and Alan J. Bitonti)

The diverse roles of FcRn: implications for antibody engineering (Sally Ward and Raimund J. Ober)

Half-life extension by fusion to albumin (Hubert J. Metzner, Thomas Weimer and Stefan Schulte)

AlbudAb(TM) technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives (Christopher Herring and Oliver Schon)

Half-life extension by binding to albumin through an albumin-binding domain (Fredrik Frejd)

Half-life extension by binding to albumin through small molecules (Sabrina Trüssel, Joerg Scheuermann and Dario Neri)

HALF-LIFE EXTENSION WITH PHARMACEUTICAL FORMULATIONS
Half-life extension with pharmaceutical formulations: liposomes (Astrid Hartung and Gerd Bendas)

Half-life extension with pharmaceutical formulations: nanoparticles (Katharina Landfester)